Exclusive Summary

• - Off-patent globally (US ~2015, EU 2016–2017) with generics since 2014+, making it a mature entry window;
• - ~254 million living with chronic HBV and ~1.1 million deaths/year, yet only ~3% treated, indicating large scalable demand;
• - Listed on the WHO EML and recommended as first-line by AASLD/EASL/APASL; 0.5mg/1.0mg strengths cover naïve and LAM-resistant/decompensated patients;
• - Strong quality signal: US registration (ANDA 216857) plus FDA/EMA GMP enables reliance approvals and high-bar tenders globally;
• - Typically 80–95% cheaper than originator, with >90% net price erosion in the US, delivering compelling pharmacoeconomic value.